Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

May 1, 2028

Study Completion Date

May 1, 2028

Conditions

Relapse Leukemia

Interventions

DRUG

VAH

For R/R AML patients, VAH bridging to conditioning regimen for allo-HCT.

Trial Locations (1)

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors

lead

Ruijin Hospital

OTHER